Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropinirole implant
- Development stage
- Preclinical
- Lead developer
- Titan Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Subdermal
01
Overview
Ropinirole implant is a long-acting, subdermal drug delivery system designed to provide continuous, non-fluctuating levels of the dopamine agonist ropinirole for up to three months. Ropinirole itself is a non-ergoline D2/D3 dopamine receptor agonist that stimulates striatal dopamine receptors and is used primarily in the management of Parkinson's disease and restless legs syndrome. The implant formulation aims to improve patient outcomes by maintaining consistent blood levels of medication, potentially reducing dosing frequency and improving symptom control compared to oral formulations. The technology platform used for this implant is ProNeura, developed by Titan Pharmaceuticals[4][5][8].
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on ropinirole implant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropinirole implant.